Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant Glioma
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
Objectives:
To define role of O6-Benzylguanine (BG) in restoring Temodar (temozolomide) sensitivity in
patients with Temodar-resistant malignant glioma.
To further define toxicity of combo therapy using Temodar + BG.
Phase:
Phase 2
Details
Lead Sponsor:
Duke University
Collaborators:
Keryx / AOI Pharmaceuticals, Inc. National Institutes of Health (NIH)